CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on December 13, 2006
Clinical Journal of the American Society of Nephrology
© 2006 American Society of Nephrology
doi: 10.2215/CJN.02400706
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.02400706v1
2/1/58    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benck, U.
Right arrow Articles by van der Woude, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benck, U.
Right arrow Articles by van der Woude, F. J.
Related Collections
Right arrowRelated Article

Received July 12, 2006
Accepted on October 26, 2006

ORIGINAL ARTICLES

Proteinuria-Lowering Effect of Heparin Therapy in Diabetic Nephropathy without Affecting the Renin-Angiotensin-Aldosterone System

Urs Benck *1, Sarah Haeckel *, John H. Clorius {dagger}, and Fokko J. van der Woude *

*V. Department of Medicine, University Hospital Mannheim, Mannheim, and {dagger}Department of Nuclear Medicine, German Cancer Research Center Heidelberg, Heidelberg, Germany


1 To whom correspondence should be addressed. E-mail: urs.benck{at}med5.ma.uni-heidelberg.de.


   Abstract

Angiotensin-converting enzyme inhibitors and angiotensin II (AngII) type 1 receptor blockers lower proteinuria and preserve renal function in diabetic nephropathy (DN). The antiproteinuric effects are greater than their blood pressure reduction, involving the sieving properties of the glomerular filter. In DN, glomerular staining for heparan sulfate proteoglycans is decreased. AngII inhibits heparan sulfate synthesis. Also, heparins modulate AngII signaling in glomerular cells, inhibiting aldosterone synthesis and lowering proteinuria in DN. Is the antiproteinuric effect of heparins due to its interference with the renin-angiotensin-aldosterone system? Ten volunteers each with DN and glomerulonephritis and control subjects were examined before and after low-dosage enoxaparin. Renal hemodynamics were determined with 99mTc-DTPA and 131I-hippurate clearance. Glomerular filtration rate (GFR), effective renal plasma flow, mean arterial pressure, and heart rate were measured at baseline and during AngII infusion before and after enoxaparin while on normal salt and salt restriction. Enoxaparin did not lower aldosterone levels. GFR remained stable in all groups. AngII caused a significant decrease in effective renal plasma flow, whereas mean arterial pressure and heart rate increased significantly. Enoxaparin did not influence the AngII-induced changes of renal hemodynamics during normal salt intake or salt restriction. All groups showed identical responses to AngII before and after enoxaparin. In patients with diabetes, enoxaparin caused a significant decrease in proteinuria. It is concluded that the antiproteinuric effect of heparins in DN cannot be explained via interaction with the renin-angiotensin-aldosterone system. The absence of hemodynamic changes combined with reduced proteinuria point to intrinsic alterations in the glomerular filter. The effects were seen only in DN, not in glomerulonephritis.


Related Article

Endothelin A Receptor Blockade Reduces Diabetic Renal Injury via an Anti-Inflammatory Mechanism
Jennifer M. Sasser, Jennifer C. Sullivan, Janet L. Hobbs, Tatsuo Yamamoto, David M. Pollock, Pamela K. Carmines, and Jennifer S. Pollock
J. Am. Soc. Nephrol. 2007 18: 143-154. [Abstract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Society of Nephrology.